Something could come from the Genentech collaboration at least we will know by EOY.
"Our collaboration on antimicrobials is progressing, with Genentech continuing to evaluate the leads it has
received before determining, by the end of this year, whether to licence or extend its option over
the peptides."
"We’ve also commenced one new material transfer agreement (MTA) and renewed an existing MTA". And if an existing MTA has been renewed it means that PYC must be doing something right.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.000(0.00%) |
Mkt cap ! $743.6M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.28 | $1.27 | $195.2K | 153.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13990 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 63167 | 3 |
View Market Depth
| Last trade - 14.04pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |